TABLE 1.
Baseline patient characteristics
| Variable | n = 41 |
|---|---|
| Age median (IQR) | 57 (50–67) |
| Female sex n (%) | 13 (32%) |
| Charlson comorbidity index n (%) | |
| 0 | 3 (7%) |
| 1 | 7 (17%) |
| ≥2 | 31 (76%) |
| ECOG performance status | |
| ECOG 0 n (%) | 19 (58%) |
| ECOG 1 n (%) | 13 (39%) |
| ASA physical status classification | |
| ASA 3 n (%) | 15 (38%) |
| ASA 4 n (%) | 25 (63%) |
| Primary n (%) | |
| Right and transverse colon | 12 (29%) |
| Left and sigmoid colon | 11 (27%) |
| Rectum | 18 (44%) |
| Number of liver lesions (radiology) (median, IQR) | 2 (1–3) |
| Max size liver lesions (radiology) (median, IQR) (mm) | 19 (14–31) |
| Bilateral liver lesions (radiology) n (%) | 17 (42%) |
| Preoperative CEA (median, IQR) (μg/L) | 4.7 (2.3–22) |
| Presurgical treatment (diversion) n (%) | 3 (7.3%) |
| Neoadjuvant therapy | |
| Chemotherapy n (%) | 27 (68%) |
| Number of cycles (median, IQR) | 6 (5–8) |
| Palliative intent n (%) | 9 (22%) |
| Radiation therapy n (%) | 16 (39%) |
Abbreviations: ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; ECOG, European Cooperative Oncology Group; IQR, interquartile range.